BR112022021391A2 - N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4 - Google Patents

N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4

Info

Publication number
BR112022021391A2
BR112022021391A2 BR112022021391A BR112022021391A BR112022021391A2 BR 112022021391 A2 BR112022021391 A2 BR 112022021391A2 BR 112022021391 A BR112022021391 A BR 112022021391A BR 112022021391 A BR112022021391 A BR 112022021391A BR 112022021391 A2 BR112022021391 A2 BR 112022021391A2
Authority
BR
Brazil
Prior art keywords
compounds
substituted
phenylacethamides
receptor antagonist
antagonist activity
Prior art date
Application number
BR112022021391A
Other languages
English (en)
Inventor
Bäurle Stefan
Ring Sven
Nagel Jens
Laux-Biehlmann Alexis
Nubbemeyer Reinhard
Pook Elisabeth
Wittrock Sven
Simon Walter Daryl
John Scott Robert
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR112022021391A2 publication Critical patent/BR112022021391A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

N-FENILACETAMIDAS SUBSTITUÍDAS QUE POSSUEM ATIVIDADE ANTAGONISTA A RECEPTOR DE P2X4. A presente invenção refere-se a compostos de fenilacetamida substituída de fórmula geral (I), a métodos de preparação dos ditos compostos, a compostos intermediários úteis para a preparação dos ditos compostos, a composições farmacêuticas e combinações que compreendem os ditos compostos, e ao uso dos ditos compostos para manufaturar as composições farmacêuticas para o tratamento ou a profilaxia de doenças.
BR112022021391A 2020-06-30 2021-06-28 N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4 BR112022021391A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20183306 2020-06-30
EP21151884 2021-01-15
PCT/EP2021/067713 WO2022002859A1 (en) 2020-06-30 2021-06-28 Substituted n-phenylacetamides having p2x4 receptor antagonistic activity

Publications (1)

Publication Number Publication Date
BR112022021391A2 true BR112022021391A2 (pt) 2023-01-10

Family

ID=76744840

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021391A BR112022021391A2 (pt) 2020-06-30 2021-06-28 N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4

Country Status (11)

Country Link
US (1) US20230257351A1 (pt)
EP (1) EP4172146A1 (pt)
JP (1) JP2023531283A (pt)
KR (1) KR20230031307A (pt)
CN (1) CN115996911A (pt)
AU (1) AU2021302525A1 (pt)
BR (1) BR112022021391A2 (pt)
CA (1) CA3188308A1 (pt)
IL (1) IL299346A (pt)
TW (1) TW202216667A (pt)
WO (1) WO2022002859A1 (pt)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049825A1 (ja) * 2005-10-28 2007-05-03 Kyushu University, National University Corporation P2x4 受容体アンタゴニスト
WO2008023847A1 (fr) * 2006-08-25 2008-02-28 Nippon Chemiphar Co., Ltd. Antagoniste du récepteur p2x4
EP2597088B1 (en) 2010-07-13 2017-11-01 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
SG11201404030YA (en) 2012-01-13 2014-10-30 Nippon Chemiphar Co P2x4 receptor antagonist
JP6357475B2 (ja) 2013-07-12 2018-07-11 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
EP3564217B1 (en) 2013-07-12 2021-01-27 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
WO2015088565A1 (en) 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds and methods of use thereof
WO2015088564A1 (en) 2013-12-13 2015-06-18 Sunovion Pharmaceuticals Inc. P2x4 receptor modulating compounds
US20180338980A1 (en) 2015-06-10 2018-11-29 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
PE20190913A1 (es) 2016-05-03 2019-06-26 Bayer Pharma AG Derivados aromaticos de sulfonamida
WO2018104305A1 (en) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Field of application of the invention
WO2018104307A1 (en) 2016-12-09 2018-06-14 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives and their use as anatagon i sts or negative allosteric modulators of p2x4
US10695355B2 (en) 2017-03-30 2020-06-30 University Of Connecticut Methods for pharmacologic treatment of stroke
WO2018210729A1 (en) * 2017-05-18 2018-11-22 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives as antagonists or negative allosteric modulators of p2x4 receptor
MA50448A (fr) 2017-10-29 2020-09-02 Bayer Ag Dérivés sulfonamides aromatiques pour le traitement d'un accident cérébral ischémique
EP3766497A4 (en) 2018-03-14 2021-12-08 Nippon Chemiphar Co., Ltd. MEDICINAL PRODUCTS FOR TREATMENT OF COUGH

Also Published As

Publication number Publication date
TW202216667A (zh) 2022-05-01
CA3188308A1 (en) 2022-01-06
US20230257351A1 (en) 2023-08-17
KR20230031307A (ko) 2023-03-07
CN115996911A (zh) 2023-04-21
IL299346A (en) 2023-02-01
WO2022002859A1 (en) 2022-01-06
JP2023531283A (ja) 2023-07-21
EP4172146A1 (en) 2023-05-03
AU2021302525A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
BR112022020841A2 (pt) Inibidores de kras tricíclicos fundidos
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
BR112023015527A2 (pt) Inibidores de cdk e métodos de uso destes
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112019016497A2 (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer.
BR112015024073A2 (pt) Derivados de 3-acetilamino-1-(fenil-heteroaril- aminocarbonil ou fenil-heteroarilcarbonilamino) benzeno para tratamento de doenças hiperproliferativas
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
BR112015016793A2 (pt) compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
BR112016028642A2 (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo.
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
BR112016028814A2 (pt) ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo?
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112018072755A2 (pt) composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica
BR112021024325A2 (pt) Análogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida
BR112022019057A2 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune
BR112013008211A8 (pt) Cocristais e sais de inibidores de ccr3, seu uso e composição que os compreende
BR112021011325A2 (pt) Derivados de rapamicina
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
EA202090448A1 (ru) Дигидрооксадиазиноны
BR112018072740A2 (pt) realçador de inibidores de homólogo 2 de zeste
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos